Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.